Posts Categorised PR


DCprime and PCI Biotech Announce a Research Collaboration to Explore Novel Cancer Vaccination Concepts

Leiden, The Netherlands and Oslo, Norway, September, 1st 2020 – DCprime, the front-runner in the field of relapse vaccines, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation, today announced an extensive research collaboration. Within the collaboration, DCprime and PCI Biotech will combine their know-how andpost


DCprime Extends International Roll-out of DCP-001 Into the United States

Opening of IND follows approval to study DCP-001 in multiple European countries Leiden, The Netherlands, May 13, 2020 –DCprime, the front-runner in the field of relapse vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for DCP-001, an allogeneic cancer relapse vaccine currently beingpost


DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia

Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapsepost


DCprime to Present Long-term Follow-up and Survival Data for Lead Relapse Vaccine Candidate DCP-001 in High-Risk AML and MDS Patients

Presentation at ASH Annual Meeting Shows Potential to Prolong Relapse-Free Survival and Overall Survival Using an Allogeneic Cell-based Vaccine in the Post-Remission Setting Leiden, The Netherlands, November 13, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of updated clinical results for its lead product DCP-001 at the upcoming 61stpost


DCprime Strengthens Supervisory Board with the Additions of Andrea van Elsas and Hans Preusting

Leiden, The Netherlands, April 25, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced the appointment of two highly-experienced industry veterans, Andrea van Elsas, Ph.D. and Hans Preusting, Ph.D., M.B.A, to its Supervisory Board. The newest members complement the existing Board, with Dharminder Chahal remaining Chairman and representing Van Herk Investments,post


DCprime and Radboudumc to collaborate

Leiden, The Netherlands and Nijmegen, The Netherlands, March 2019– DCprime and Radboudumc announce that they will collaborate as part of a public-private consortium supported by The Dutch Top Sector Life Sciences and Health, represented by Stichting Life Sciences Health – TKI, also acting under its trade name Health~Holland, under the project title “Dendritic Cell Targetingpost